FNICM: A New Methodology To Identify Core Metabolites Based on Significantly Perturbed Metabolic Subnetworks

• Published in: Analytical chemistry (Washington) 2024-02, Vol.96 (8), p.3335-3344
• Main Authors: Li, Qi, Yin, Ying-Hao, Liu, Zi-Wei, Liu, Li-Fang, Xin, Gui-Zhong
• Format: Article
• Language: English
• Subjects: analytical chemistry; Biomarkers; biomedical research; Clematis; Colitis, Ulcerative - diagnosis; Colorectal carcinoma; colorectal neoplasms; Computational Biology - methods; Computer networks; Confidence intervals; Datasets; disease diagnosis; drug therapy; Humans; Inflammatory bowel diseases; Medical research; Metabolism; Metabolites; Metabolomics; Metabolomics - methods; Methodology; Network topologies; Saponins; Topology; Ulcerative colitis
• ISSN: 0003-2700; 1520-6882; 1520-6882
• DOI: 10.1021/acs.analchem.3c04131

Metabolomics has emerged as a powerful tool in biomedical research to understand the pathophysiological processes and metabolic biomarkers of diseases. Nevertheless, it is a significant challenge in metabolomics to identify the reliable core metabolites that are closely associated with the occurrence or progression of diseases. Here, we proposed a new research framework by integrating detection-based metabolomics with computational network biology for function-guided and network-based identification of core metabolites, namely, FNICM. The proposed FNICM methodology is successfully utilized to uncover ulcerative colitis (UC)-related core metabolites based on the significantly perturbed metabolic subnetwork. First, seed metabolites were screened out using prior biological knowledge and targeted metabolomics. Second, by leveraging network topology, the perturbations of the detected seed metabolites were propagated to other undetected ones. Ultimately, 35 core metabolites were identified by controllability analysis and were further hierarchized into six levels based on confidence level and their potential significance. The specificity and generalizability of the discovered core metabolites, used as UC’s diagnostic markers, were further validated using published data sets of UC patients. More importantly, we demonstrated the broad applicability and practicality of the FNICM framework in different contexts by applying it to multiple clinical data sets, including inflammatory bowel disease, colorectal cancer, and acute coronary syndrome. In addition, FNICM was also demonstrated as a practicality methodology to identify core metabolites correlated with the therapeutic effects of Clematis saponins. Overall, the FNICM methodology is a new framework for identifying reliable core metabolites for disease diagnosis and drug treatment from a systemic and a holistic perspective.